无精子症中 IGSF11-AS1 和 BVES-AS 的表达失调及其与血清激素水平的相关性。

IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Biomarkers in medicine Pub Date : 2024-01-01 Epub Date: 2024-06-17 DOI:10.1080/17520363.2024.2345581
Mohammed Ismael Ibrahim Jebur, Nashwah Jabbar Kadhim Muttwaqi, Azeez Hasan Saleh Saleh, Reza Safaralizadeh
{"title":"无精子症中 IGSF11-AS1 和 BVES-AS 的表达失调及其与血清激素水平的相关性。","authors":"Mohammed Ismael Ibrahim Jebur, Nashwah Jabbar Kadhim Muttwaqi, Azeez Hasan Saleh Saleh, Reza Safaralizadeh","doi":"10.1080/17520363.2024.2345581","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Azoospermia accounts for 10-20% of male infertility. In 20-30% of affected males, genetic abnormalities are the leading cause of azoospermia. LncRNAs can regulate spermatogenic cell development. <b>Methods:</b> This study chose 76 azoospermia patients and 36 healthy males. The gene expression was examined using the qRT-PCR technique. <b>Results:</b> <i>IGSF11-AS1</i> and <i>BVES-AS</i> appeared to be considerably underexpressed in the patients; however, only <i>IGSF11-AS1</i> demonstrated a significant biomarker role. Additionally, <i>IGSF11-AS1</i> expression was positively correlated with testosterone but was negatively correlated with follicle-stimulating hormone (FSH) and luteinizing hormone (LH). For the <i>BVES-AS</i> gene, however, FSH and LH had a negative correlation. <b>Conclusion:</b> As a result of its low expression level in tissue samples, <i>IGSF11-AS1</i> has a biomarker role for early azoospermia detection.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"485-492"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285263/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dysregulated expression of IGSF11-AS1 and BVES-AS in azoospermia and its correlation with serum hormone levels.\",\"authors\":\"Mohammed Ismael Ibrahim Jebur, Nashwah Jabbar Kadhim Muttwaqi, Azeez Hasan Saleh Saleh, Reza Safaralizadeh\",\"doi\":\"10.1080/17520363.2024.2345581\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Azoospermia accounts for 10-20% of male infertility. In 20-30% of affected males, genetic abnormalities are the leading cause of azoospermia. LncRNAs can regulate spermatogenic cell development. <b>Methods:</b> This study chose 76 azoospermia patients and 36 healthy males. The gene expression was examined using the qRT-PCR technique. <b>Results:</b> <i>IGSF11-AS1</i> and <i>BVES-AS</i> appeared to be considerably underexpressed in the patients; however, only <i>IGSF11-AS1</i> demonstrated a significant biomarker role. Additionally, <i>IGSF11-AS1</i> expression was positively correlated with testosterone but was negatively correlated with follicle-stimulating hormone (FSH) and luteinizing hormone (LH). For the <i>BVES-AS</i> gene, however, FSH and LH had a negative correlation. <b>Conclusion:</b> As a result of its low expression level in tissue samples, <i>IGSF11-AS1</i> has a biomarker role for early azoospermia detection.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"485-492\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285263/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2024.2345581\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2345581","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:无精子症占男性不育症的 10-20%。在20%-30%的男性患者中,遗传异常是导致无精子症的主要原因。LncRNA 可调控生精细胞的发育。研究方法本研究选择了 76 名无精子症患者和 36 名健康男性。采用 qRT-PCR 技术检测基因表达。结果显示IGSF11-AS1和BVES-AS在患者体内的表达量明显不足;然而,只有IGSF11-AS1显示出显著的生物标记作用。此外,IGSF11-AS1的表达与睾酮呈正相关,但与卵泡刺激素(FSH)和黄体生成素(LH)呈负相关。而 BVES-AS 基因与 FSH 和 LH 呈负相关。结论由于其在组织样本中的低表达水平,IGSF11-AS1 在早期无精子症检测中具有生物标记作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dysregulated expression of IGSF11-AS1 and BVES-AS in azoospermia and its correlation with serum hormone levels.

Aim: Azoospermia accounts for 10-20% of male infertility. In 20-30% of affected males, genetic abnormalities are the leading cause of azoospermia. LncRNAs can regulate spermatogenic cell development. Methods: This study chose 76 azoospermia patients and 36 healthy males. The gene expression was examined using the qRT-PCR technique. Results: IGSF11-AS1 and BVES-AS appeared to be considerably underexpressed in the patients; however, only IGSF11-AS1 demonstrated a significant biomarker role. Additionally, IGSF11-AS1 expression was positively correlated with testosterone but was negatively correlated with follicle-stimulating hormone (FSH) and luteinizing hormone (LH). For the BVES-AS gene, however, FSH and LH had a negative correlation. Conclusion: As a result of its low expression level in tissue samples, IGSF11-AS1 has a biomarker role for early azoospermia detection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biomarkers in medicine
Biomarkers in medicine 医学-医学:研究与实验
CiteScore
3.80
自引率
4.50%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信